EPIDEMIOLOGIC AND CLINICAL CHARACTERISTICS OF MULTIPLE MYELOMA IN FIVE REGIONS OF RUSSIAN FEDERATION
(Abstract release date: 05/21/15)
EHA Library. Mendeleeva L. 06/12/15; 102967; PB1885
Larisa Mendeleeva
Contributions
Contributions
Abstract
Abstract: PB1885
Type: Publication Only
Background
Multiple myeloma (MM) is an incurable hematological disease previously associated with poor prognosis and survival rates. MM accounts for 15% of all hematologic malignancies and 2% of all malignancies. In Europe it affects about 4 per 100 000 individuals each year. The total number of patients in Russian Federation is still unknown. Epidemiological cancer registries are institutions for the collection, storage, processing, analysis and interpretation of data on the incidence and prevalence of cancers within defined registration areas. The data from the cancer registries also forms an indispensable basis for further studies into the assessment of early detection measures and population-based care of tumour patients.
Aims
Methods
170 patients with multiple myeloma from 5 different regions of Russian Federation (Tul’skaya region, Vologodskaya region, Tverskaya region, Mordoviya republic and Amurskaya region) diagnosed from January 01, 2009 to January 01, 2012 were included in the study. Data regarding these patients were extracted from prospectively maintained databases and review of medical records. Follow-up information on these patients was collected prospectively and entered at the time of each visit. Response was defined according to IMWG criteria. Kaplan-Meier analysis was used for analyzing overall survival. The cutoff date for the interim analysis was January 22, 2014.
Results
Among 170 pts, there were 68 men and 102 women, aged from 42 to 86 years (median 61 year). 48,9% of pts were less than 60 years. There were 55% pts with myeloma G, 19% with myeloma A, 13% with light-chain myeloma, 1% with myeloma D, 3% with myeloma M, 2% with non-secretory myeloma, 5% pts with diclonaly myeloma and in 2% of pts the type of MM was not defined. 85 (50%) pts were in stage III, 77 (45%) pts were in stage II and only 8 (5%) of pts in stage I. At the time of diagnosis 36 (21%) pts had signs of renal failure (serum creatinine more 177 mmol/l). Information about treatment and treatment responses was available in 153 cases. 97% of pts proceeded induction therapy: 84% pts – bortezomib-containing treatment, 13% - conventional therapy and 3% refused of treatment. High-dose therapy with autologous stem cell transplantation was performed only in 14 cases due to remoteness from transplant centers. Overall response was achieved in 68% of pts, among them complete remission – in 26%. Absolute 5-year overall survival rate in our group was 37%±6,3% (median 41,7 months). No difference was seen in overall survival between men and women. There was a trend of increase of 3-year overall survival in pts diagnosed in 2011 in compare with pts diagnosed in 2009 (65,5% vs 46,4%). 71of 170 pts are still alive. The main reasons of deaths were disease progression (70%), concomitant illnesses (21%) and inflectional complications (5%).
Summary
Keyword(s): Epidemiology, Multiple myeloma
Session topic: Publication Only
Type: Publication Only
Background
Multiple myeloma (MM) is an incurable hematological disease previously associated with poor prognosis and survival rates. MM accounts for 15% of all hematologic malignancies and 2% of all malignancies. In Europe it affects about 4 per 100 000 individuals each year. The total number of patients in Russian Federation is still unknown. Epidemiological cancer registries are institutions for the collection, storage, processing, analysis and interpretation of data on the incidence and prevalence of cancers within defined registration areas. The data from the cancer registries also forms an indispensable basis for further studies into the assessment of early detection measures and population-based care of tumour patients.
Aims
To define epidemiologic and clinical characteristics of MM in 5 different regions in Russian Federation.
Methods
170 patients with multiple myeloma from 5 different regions of Russian Federation (Tul’skaya region, Vologodskaya region, Tverskaya region, Mordoviya republic and Amurskaya region) diagnosed from January 01, 2009 to January 01, 2012 were included in the study. Data regarding these patients were extracted from prospectively maintained databases and review of medical records. Follow-up information on these patients was collected prospectively and entered at the time of each visit. Response was defined according to IMWG criteria. Kaplan-Meier analysis was used for analyzing overall survival. The cutoff date for the interim analysis was January 22, 2014.
Results
Among 170 pts, there were 68 men and 102 women, aged from 42 to 86 years (median 61 year). 48,9% of pts were less than 60 years. There were 55% pts with myeloma G, 19% with myeloma A, 13% with light-chain myeloma, 1% with myeloma D, 3% with myeloma M, 2% with non-secretory myeloma, 5% pts with diclonaly myeloma and in 2% of pts the type of MM was not defined. 85 (50%) pts were in stage III, 77 (45%) pts were in stage II and only 8 (5%) of pts in stage I. At the time of diagnosis 36 (21%) pts had signs of renal failure (serum creatinine more 177 mmol/l). Information about treatment and treatment responses was available in 153 cases. 97% of pts proceeded induction therapy: 84% pts – bortezomib-containing treatment, 13% - conventional therapy and 3% refused of treatment. High-dose therapy with autologous stem cell transplantation was performed only in 14 cases due to remoteness from transplant centers. Overall response was achieved in 68% of pts, among them complete remission – in 26%. Absolute 5-year overall survival rate in our group was 37%±6,3% (median 41,7 months). No difference was seen in overall survival between men and women. There was a trend of increase of 3-year overall survival in pts diagnosed in 2011 in compare with pts diagnosed in 2009 (65,5% vs 46,4%). 71of 170 pts are still alive. The main reasons of deaths were disease progression (70%), concomitant illnesses (21%) and inflectional complications (5%).
Summary
Our study showed that the median of age of pts with newly diagnosed MM in Russian Federation is 10 years less than in Europe and USA. Absolute 5-year overall survival rate in our pts is 37% that is comparable with MM pts in Germany (39%).
Keyword(s): Epidemiology, Multiple myeloma
Session topic: Publication Only
Abstract: PB1885
Type: Publication Only
Background
Multiple myeloma (MM) is an incurable hematological disease previously associated with poor prognosis and survival rates. MM accounts for 15% of all hematologic malignancies and 2% of all malignancies. In Europe it affects about 4 per 100 000 individuals each year. The total number of patients in Russian Federation is still unknown. Epidemiological cancer registries are institutions for the collection, storage, processing, analysis and interpretation of data on the incidence and prevalence of cancers within defined registration areas. The data from the cancer registries also forms an indispensable basis for further studies into the assessment of early detection measures and population-based care of tumour patients.
Aims
Methods
170 patients with multiple myeloma from 5 different regions of Russian Federation (Tul’skaya region, Vologodskaya region, Tverskaya region, Mordoviya republic and Amurskaya region) diagnosed from January 01, 2009 to January 01, 2012 were included in the study. Data regarding these patients were extracted from prospectively maintained databases and review of medical records. Follow-up information on these patients was collected prospectively and entered at the time of each visit. Response was defined according to IMWG criteria. Kaplan-Meier analysis was used for analyzing overall survival. The cutoff date for the interim analysis was January 22, 2014.
Results
Among 170 pts, there were 68 men and 102 women, aged from 42 to 86 years (median 61 year). 48,9% of pts were less than 60 years. There were 55% pts with myeloma G, 19% with myeloma A, 13% with light-chain myeloma, 1% with myeloma D, 3% with myeloma M, 2% with non-secretory myeloma, 5% pts with diclonaly myeloma and in 2% of pts the type of MM was not defined. 85 (50%) pts were in stage III, 77 (45%) pts were in stage II and only 8 (5%) of pts in stage I. At the time of diagnosis 36 (21%) pts had signs of renal failure (serum creatinine more 177 mmol/l). Information about treatment and treatment responses was available in 153 cases. 97% of pts proceeded induction therapy: 84% pts – bortezomib-containing treatment, 13% - conventional therapy and 3% refused of treatment. High-dose therapy with autologous stem cell transplantation was performed only in 14 cases due to remoteness from transplant centers. Overall response was achieved in 68% of pts, among them complete remission – in 26%. Absolute 5-year overall survival rate in our group was 37%±6,3% (median 41,7 months). No difference was seen in overall survival between men and women. There was a trend of increase of 3-year overall survival in pts diagnosed in 2011 in compare with pts diagnosed in 2009 (65,5% vs 46,4%). 71of 170 pts are still alive. The main reasons of deaths were disease progression (70%), concomitant illnesses (21%) and inflectional complications (5%).
Summary
Keyword(s): Epidemiology, Multiple myeloma
Session topic: Publication Only
Type: Publication Only
Background
Multiple myeloma (MM) is an incurable hematological disease previously associated with poor prognosis and survival rates. MM accounts for 15% of all hematologic malignancies and 2% of all malignancies. In Europe it affects about 4 per 100 000 individuals each year. The total number of patients in Russian Federation is still unknown. Epidemiological cancer registries are institutions for the collection, storage, processing, analysis and interpretation of data on the incidence and prevalence of cancers within defined registration areas. The data from the cancer registries also forms an indispensable basis for further studies into the assessment of early detection measures and population-based care of tumour patients.
Aims
To define epidemiologic and clinical characteristics of MM in 5 different regions in Russian Federation.
Methods
170 patients with multiple myeloma from 5 different regions of Russian Federation (Tul’skaya region, Vologodskaya region, Tverskaya region, Mordoviya republic and Amurskaya region) diagnosed from January 01, 2009 to January 01, 2012 were included in the study. Data regarding these patients were extracted from prospectively maintained databases and review of medical records. Follow-up information on these patients was collected prospectively and entered at the time of each visit. Response was defined according to IMWG criteria. Kaplan-Meier analysis was used for analyzing overall survival. The cutoff date for the interim analysis was January 22, 2014.
Results
Among 170 pts, there were 68 men and 102 women, aged from 42 to 86 years (median 61 year). 48,9% of pts were less than 60 years. There were 55% pts with myeloma G, 19% with myeloma A, 13% with light-chain myeloma, 1% with myeloma D, 3% with myeloma M, 2% with non-secretory myeloma, 5% pts with diclonaly myeloma and in 2% of pts the type of MM was not defined. 85 (50%) pts were in stage III, 77 (45%) pts were in stage II and only 8 (5%) of pts in stage I. At the time of diagnosis 36 (21%) pts had signs of renal failure (serum creatinine more 177 mmol/l). Information about treatment and treatment responses was available in 153 cases. 97% of pts proceeded induction therapy: 84% pts – bortezomib-containing treatment, 13% - conventional therapy and 3% refused of treatment. High-dose therapy with autologous stem cell transplantation was performed only in 14 cases due to remoteness from transplant centers. Overall response was achieved in 68% of pts, among them complete remission – in 26%. Absolute 5-year overall survival rate in our group was 37%±6,3% (median 41,7 months). No difference was seen in overall survival between men and women. There was a trend of increase of 3-year overall survival in pts diagnosed in 2011 in compare with pts diagnosed in 2009 (65,5% vs 46,4%). 71of 170 pts are still alive. The main reasons of deaths were disease progression (70%), concomitant illnesses (21%) and inflectional complications (5%).
Summary
Our study showed that the median of age of pts with newly diagnosed MM in Russian Federation is 10 years less than in Europe and USA. Absolute 5-year overall survival rate in our pts is 37% that is comparable with MM pts in Germany (39%).
Keyword(s): Epidemiology, Multiple myeloma
Session topic: Publication Only
{{ help_message }}
{{filter}}